Humacyte, Inc. (HUMA) Profit Margins
Over the twelve months to 2026-06-30, Humacyte, Inc. (HUMA) had operating margin -5240.8%, net margin -4560.8%, free cash flow margin -4599.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
HUMAHumacyte, Inc.Follow HUMA — free
—
Price chart with a free account
- Market cap
- 121.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 6 Nov, in 13 days
| Line | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|
| Gross margin | -376.1% | — | |
| Operating margin | -5306.0% | -5240.8% | |
| Net margin | -2003.6% | -4560.8% | |
| FCF margin | -5197.5% | -4599.7% |
USD millions · SEC XBRL
Humacyte, Inc. — questions
- What is Humacyte, Inc.'s operating margin?
- -5240.8% over the twelve months to 2026-06-30.
- What is Humacyte, Inc.'s net profit margin?
- -4560.8% over the twelve months to 2026-06-30.
Every figure on this page comes from Humacyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.